Bosco & Crossy's stock picks,talk area Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PuddleGlum who wrote (3466)	6/23/2003 9:04:09 AM
From: Crossy	Read Replies (1) of 37387

re: NasdaqNM: GORX (Innovative Companies) Puddleglum, these are really good numbers - the company earned $0.02 this quarter DESPITE the ramp up, legal and engineering effort to establish their generics franchise and despite the costs (such listing fees) of obtaining nationwide distribution for their "branded" nutritional product offerings... Breaking out the 4th quarter revenues were around $3.8m and earnings at EPS $0.02. Total year, revenues of $14.7m (+64% vs. last year), earnings of $1m - EPS $0.15. The biz model I really do like - "balanced" growth - upfront nutraceutics, later on generics as an "afterburner". Given these fundamentals, it's entirely possible that GORX will ultimately outperform Medifast (Amex: MED) down the road.. rgrds CROSSY

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next